SCHEMBL315649

SCHEMBL315649

CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)CS[C@H]1Oc1cncc(-c2cccnc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB1 P11230 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNB3 Q05901 1/20 0.37
CYP11B2 P19099 5/20 0.37
CYP11B1 P15538 3/20 0.37
CYP19A1 P11511 1/20 0.37
MKNK1 Q9BUB5 7/20 0.36
MKNK2 Q9HBH9 7/20 0.36
ABL1 P00519 2/20 0.35
OPRM1 P35372 1/20 0.35
KCNH2 Q12809 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2A6 P11509 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
BCR P11274 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL315650 1.00 CHRNB1 (0.37) CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3
SCHEMBL2411065 0.92 CYP11B1 (0.39) CYP11B2CYP11B1CYP19A1MKNK1MKNK2
SCHEMBL2411071 0.92 CYP11B1 (0.39) CYP11B2CYP11B1CYP19A1MKNK1MKNK2
SCHEMBL2139085 0.92 CHRNB2 (0.36) CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3
SCHEMBL2139089 0.92 CHRNB2 (0.36) CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3
SCHEMBL314632 0.90 MKNK1 (0.34) CYP11B2CYP11B1MKNK1MKNK2
SCHEMBL2410664 0.90 CYP19A1 (0.38) CYP11B2CYP11B1CYP19A1MKNK1MKNK2
SCHEMBL314631 0.90 MKNK1 (0.34) CYP11B2CYP11B1MKNK1MKNK2
SCHEMBL2410659 0.90 CYP19A1 (0.38) CYP11B2CYP11B1CYP19A1MKNK1MKNK2
SCHEMBL316063 0.88 CHRNB1 (0.34) CHRNB1CHRNB2CHRNB4CHRNA3CHRNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093394-B2 Derivatives of 5-thioxylopyranose and use of same for treatment LABORATOIRES FOURNIER S.A. (FR) 2012-01-10 US disclosed
EP-2066683-B1 DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT FOURNIER LAB SA (FR) 2010-11-03 EP disclosed
US-20090182013-A1 Derivatives of 5-Thioxylopyranose and Use of Same for Treatment LABORATOIRES FOURNIER S.A. (FR) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182013-A1 Derivatives of 5-Thioxylopyranose and Use of Same for Treatment TPMT, PNPO, PPOX CHRNB1 4583/4885CHRNB2 4851/4885CHRNB4 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.